A version of this story originally appeared in The Readout, STAT’s biotech newsletter. Sign up here.

Dr. David Hung has had a distinguished career in biotech, presiding over the development of a blockbuster cancer drug and flipping a company for $14 billion. But the last act, in which he led an Alzheimer’s disease startup through a catastrophic failure, is one from which he’d like to move on.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • NELO data will be spectacular
    Its from the ARNA labs
    GPCR technology is 3 for 3 all best in class
    Ralenepig
    Entresimod
    Belviq
    Soon Apd 371 Non opioid pain Non addictive

    He left too soon

  • Jumping on Axovant ship he proved that the first time around he got either unbelievably lucky, or he was just a street smart. Either way, he must be a mediocre scientist/physician.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy